Psychedelic Rally: Stocks Surge as FDA Ramps Up Reviews
Shares of psychedelic drug developers soared following an executive order by U.S. President Donald Trump calling for faster FDA reviews and increased funding. AtaiBeckley stocks jumped 28%, Compass Pathways rose 37%, Enveric BioSciences surged 140%, and GH Research climbed 24%. This rapid investment signals growing interest in psychedelics.
In recent health news, psychedelic drug developers experienced a significant surge in stock prices. This uptick followed President Donald Trump's executive order instructing the FDA to accelerate the review process for psychedelic treatments. Additionally, federal support for psychedelic research is set to increase, signaling a potential shift in research and treatment paradigms.
The market responded swiftly, with AtaiBeckley seeing a 28% jump in its stock prices, while Compass Pathways' shares climbed 37%. Enveric BioSciences reported an extraordinary 140% rise, and GH Research experienced a 24% increase. These gains reflect heightened investor interest driven by anticipated regulatory and research advancements.
This move by the Trump administration marks a pivotal point for psychedelic drug research and development, highlighting the growing acceptance and potential these treatments possess within the pharmaceutical sector.
ALSO READ
-
U.S. News Highlights: From Fed Chief Nomination to Psychedelic Drug Surge
-
Psychedelic Drug Developers Surge as Trump Expedites FDA Reviews
-
Global Health Highlights: Corporate Moves, Psychedelic Progress, and Product Safety Alerts
-
Trump's Psychedelic Leap, Poisoned Baby Food Scare, and UCB's Strategic Buy
-
CRISPR Progress and Psychedelics in Spotlight Amid Biotech Surge
Google News